Brokerages expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to announce $4.39 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $4.21 billion to $4.77 billion. Regeneron Pharmaceuticals reported sales of $2.42 billion during the same quarter last year, which indicates a positive year over year growth rate of 81.4%. The firm is expected to issue its next quarterly earnings report on Friday, February 4th.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $15.22 billion for the current financial year, with estimates ranging from $13.44 billion to $15.89 billion. For the next financial year, analysts forecast that the business will report sales of $12.83 billion, with estimates ranging from $11.56 billion to $14.93 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, November 4th. The biopharmaceutical company reported $15.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.81 by $5.56. The firm had revenue of $3.45 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 50.38% and a net margin of 51.65%. The company’s revenue was up 50.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $7.68 earnings per share.
Shares of REGN traded down $1.14 during mid-day trading on Friday, hitting $648.18. The company’s stock had a trading volume of 545,233 shares, compared to its average volume of 850,101. Regeneron Pharmaceuticals has a one year low of $441.00 and a one year high of $686.62. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.16 and a current ratio of 3.71. The firm has a market capitalization of $69.71 billion, a PE ratio of 10.35, a price-to-earnings-growth ratio of 1.16 and a beta of 0.19. The stock’s 50-day moving average is $606.80 and its two-hundred day moving average is $588.14.
In other news, Director Joseph L. Goldstein sold 2,479 shares of the firm’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $650.00, for a total value of $1,611,350.00. Following the completion of the sale, the director now directly owns 8,370 shares in the company, valued at $5,440,500. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Friday, October 1st. The shares were sold at an average price of $576.75, for a total value of $576,750.00. The disclosure for this sale can be found here. Insiders have sold 46,079 shares of company stock valued at $30,010,914 over the last quarter. Corporate insiders own 11.84% of the company’s stock.
A number of institutional investors have recently bought and sold shares of REGN. Putnam Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 43.1% in the third quarter. Putnam Investments LLC now owns 1,342,754 shares of the biopharmaceutical company’s stock valued at $812,608,000 after acquiring an additional 404,567 shares during the last quarter. BlackRock Inc. boosted its holdings in Regeneron Pharmaceuticals by 3.7% in the third quarter. BlackRock Inc. now owns 9,366,862 shares of the biopharmaceutical company’s stock valued at $5,668,639,000 after acquiring an additional 333,312 shares during the last quarter. Amundi bought a new position in Regeneron Pharmaceuticals in the second quarter valued at about $112,501,000. Point72 Asset Management L.P. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at about $105,396,000. Finally, Sivik Global Healthcare LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $5,787,000. Institutional investors and hedge funds own 82.08% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.
Read More: Is the QQQ ETF safe?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.